Herpes simplex virus during pregnancy poses a real but manageable risk, and the distinction that matters most is timing: a new infection acquired close to delivery is far more dangerous to the baby than a long-standing one. Most women with recurrent genital herpes deliver healthy infants, especially when antiviral medication and careful delivery planning are part of the picture. The biology behind why timing matters, and the practical steps that reduce transmission, are worth understanding in detail.
Why a New Infection Is Far Riskier Than an Old One
The single most important factor in whether HSV passes from mother to baby is whether the mother’s infection is new or long-established. Women who pick up a primary or first-episode genital herpes infection during pregnancy face a much higher chance of transmitting the virus than women who have had recurrent outbreaks for years.1PubMed Central. Mother-to-Child Transmission of Herpes Simplex Virus The reason comes down to antibodies. When you have carried HSV for months or years, your immune system has built up a stockpile of virus-specific antibodies. Those antibodies cross the placenta and give the baby a degree of passive protection. A brand-new infection, by contrast, catches the immune system flat-footed. The mother has not yet developed a robust antibody response, so neither she nor the baby has much defense when the virus is at its most active.
This is especially concerning in the third trimester. A primary infection acquired in the weeks before delivery combines high viral loads with minimal maternal antibody, creating the worst-case scenario for transmission. A first-episode infection earlier in pregnancy still carries elevated risk, but the mother has more time to mount an immune response before the baby arrives.
How the Virus Reaches the Baby
Transmission during pregnancy itself, while the baby is still in the uterus, is rare. The overwhelming majority of neonatal herpes cases happen during labor and delivery, when the baby passes through a birth canal where the virus is present.2PubMed Central. Herpes simplex virus infection in pregnancy Direct contact with infected genital secretions or active lesions is the primary route. In uncommon cases, the virus can also reach the baby after birth through contact with someone who has an active oral or genital herpes outbreak, but the delivery itself is the main danger zone.
What makes this tricky is that many women shed the virus without knowing it. In a large study of nearly 16,000 women who had no symptoms or visible signs of genital herpes at the time of labor, viral cultures came back positive in 57 of them.3PubMed. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor A separate study found that among women shedding the virus asymptomatically at delivery, about a third had serologic evidence of a recently acquired infection they did not know about, while the rest had reactivation of an existing infection.4PubMed. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor Because viral infection and reactivation are frequently silent, many affected women have no idea they carry a risk of passing the virus to their infant.
Detecting this invisible shedding is harder than it sounds. Standard viral cultures miss a lot of cases. When researchers compared culture to PCR testing during the third trimester, asymptomatic shedding showed up in about 14% of samples by PCR but only about 2% by culture.5PubMed. Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy That gap means that even testing close to delivery can underestimate how often the virus is present.
Antiviral Medication in Late Pregnancy
For women with a known history of genital herpes, starting suppressive antiviral therapy around 36 weeks of gestation is now standard practice. The goal is to reduce the chance of an outbreak at delivery and to lower the amount of virus being shed from the genital tract. Acyclovir and valacyclovir are the two drugs used most often, and both have solid trial data behind them.
In one randomized trial, women who took valacyclovir from 36 weeks onward had clinical recurrences only about 11% of the time before delivery, compared with 27% in the placebo group.6American Journal of Obstetrics & Gynecology. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women Another trial testing acyclovir found that none of the women on the drug had positive viral cultures near delivery, versus 7% in the placebo group, and PCR detection dropped from 34% to 2%.7PubMed. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery A third trial found that acyclovir cut the odds of clinical recurrences or asymptomatic shedding during treatment by roughly two-thirds.8PubMed. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection
These drugs also reduce the number of cesarean deliveries performed for herpes-related reasons, since fewer women have visible lesions when labor begins. That matters because avoiding unnecessary surgery has its own health benefits for both mother and baby.
Are These Drugs Safe During Pregnancy?
This is one of the most common concerns, and the reassurance here is strong. A large Danish registry study looked at over 1,800 pregnancies exposed to acyclovir, valacyclovir, or famciclovir during the first trimester and found a birth defect rate of about 2.2%, compared with 2.4% in unexposed pregnancies. After adjusting for other factors, there was no increased risk of major birth defects.9JAMA. Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects Data from an international acyclovir pregnancy registry spanning 15 years reached the same conclusion: the rates and types of birth defects in exposed pregnancies did not differ from the general population.10PubMed. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999
This safety profile is one reason suppressive therapy has become routine rather than controversial. The drugs are used in the third trimester for suppression, but even first-trimester exposure for a primary outbreak does not appear to cause harm. That said, prescribing in the first trimester is usually reserved for situations where the clinical need is clear, such as a severe primary episode.
How Delivery Decisions Are Made
Current guidelines call for cesarean delivery when a woman has active genital HSV lesions or prodromal symptoms at the time of labor.11PubMed Central. Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy The logic is straightforward: the baby’s main exposure happens in the birth canal, so bypassing it removes much of the risk. Data from a large prospective study showed that cesarean delivery dropped the transmission rate among women who were shedding the virus from roughly 8% to about 1%.12JAMA. Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant
An interesting finding from that same study: among women who had visible genital lesions and delivered by cesarean, none transmitted the virus to their infants. The highest-risk group turned out to be women who were shedding the virus without any lesions, because their shedding went undetected and they delivered vaginally. This reinforces why suppressive antiviral therapy matters even in the absence of symptoms.
Certain obstetric procedures can also increase risk. Fetal scalp electrodes, used for internal fetal monitoring, create a break in the baby’s skin and can introduce the virus directly. Case reports have documented severe neonatal infections traced to the electrode placement site.13PubMed. Neonatal herpes simplex virus infection introduced by fetal-monitor scalp electrodes For women with known genital herpes, clinicians generally avoid invasive monitoring devices and procedures that could increase the baby’s exposure.
What Neonatal Herpes Looks Like
When a newborn does contract HSV, the infection falls into one of three categories based on severity, and the category has a direct relationship to how sick the baby gets.14NeoReviews. Neonatal Herpes Simplex Virus Infection
- SEM disease: Limited to the skin, eyes, and mouth. This is the least dangerous form, though it still requires treatment to prevent progression.
- CNS disease: Involves the brain, with or without skin findings, but no widespread organ involvement. This category carries the highest risk of long-term neurological problems.
- Disseminated disease: Spreads to multiple organs including the lungs, liver, and adrenal glands, often with brain involvement as well. This form has the highest mortality rate.
The challenge is that early symptoms can be maddeningly nonspecific. A newborn with HSV may initially look like any sick infant with fever, poor feeding, or irritability. The range of presentations is wide enough that clinicians need a high level of suspicion to catch it early, especially in cases without the telltale skin blisters.15PubMed Central. The Many Faces of Neurological Neonatal Herpes Simplex Virus Infection Treatment with intravenous acyclovir should be started as soon as neonatal herpes is suspected, and higher doses have been shown to improve survival. In trials comparing high-dose to standard-dose acyclovir for disseminated disease, babies on the higher dose were over three times more likely to survive.16PubMed. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections – Section: RESULTS
Long-Term Outcomes for Affected Infants
Even when neonatal herpes is treated and the baby survives, the long-term effects can be substantial, particularly when the brain has been involved. One study found that herpes encephalitis in newborns had a greater impact on cognitive function, speech, and attention than researchers had anticipated, with social skills affected to a lesser degree.17PubMed. Neuropsychologic outcomes in children with neonatal herpes encephalitis Relapses were documented in some children, leading to further deterioration.
A more recent study of children who had HSV-related brain infections found that about three-quarters had long-term neurological problems at follow-up. Some children who appeared neurologically normal at the time of hospital discharge went on to develop problems later, underscoring the need for ongoing monitoring.18PubMed Central. Epidemiology and long‐term neurological sequelae of childhood herpes simplex CNS infection This delayed emergence of deficits is something parents and pediatricians should be aware of: a clean bill of health at discharge does not guarantee everything is fine long-term when the brain has been involved.
Why Routine Screening Still Is Not Recommended
Given everything above, you might wonder why doctors do not just test all pregnant women for HSV antibodies at their first prenatal visit. The U.S. Preventive Services Task Force has looked at this question and reaffirmed its recommendation against routine serologic screening for genital herpes in asymptomatic people, including pregnant women.19PubMed Central. Reaffirmed USPSTF Recommendation Against Serologic Screening for Genital Herpes: Empowering Clinicians and Reducing Potential Harm The reasoning is that the available blood tests produce too many false-positive results, and there is no evidence that screening asymptomatic pregnant women actually improves outcomes for their babies. The psychological toll of a false or unexpected positive result, including anxiety, stigma, and relationship disruption, is a documented harm with no offsetting proven benefit at the population level.
This does not mean testing has no role. Women who develop suspicious symptoms during pregnancy should absolutely be tested. And type-specific serologic testing can be useful in specific clinical scenarios, such as when a woman’s partner has known genital herpes and she does not know her own status. The recommendation is against blanket screening, not against targeted testing when there is a reason for it.
Protecting Yourself from a New Infection During Pregnancy
Because a new infection is the highest-risk scenario, preventing HSV acquisition during pregnancy is arguably more important than managing an existing infection. Couples where one partner has genital herpes and the other does not face a real and measurable transmission risk during pregnancy.20PubMed. Risk factors for herpes simplex virus transmission to pregnant women: a couples study The tricky part is that many people carry HSV without knowing it, so clinical history alone cannot reliably identify who is at risk.
One study found that when couples learned through blood testing that they were in a serodiscordant relationship for HSV-2, the pregnant women reported significantly less unprotected sex compared with women who did not know their partner’s status.21The Journal of Infectious Diseases. A Prospective Cohort Study of Partner Testing for Herpes Simplex Virus and Sexual Behavior During Pregnancy In practical terms, knowing your partner’s HSV status changes behavior in a way that could prevent new infections. For HSV-1 serodiscordance, the behavioral changes were not as clear, possibly because people do not perceive oral herpes as carrying the same genital risk during pregnancy, even though HSV-1 genital infections are increasingly common.
Condom use and avoiding sex during active outbreaks are standard advice for discordant couples, and these precautions become especially important during the third trimester. Some clinicians also recommend that a partner with known genital herpes take daily suppressive antiviral therapy during the pregnancy, though this approach targets the partner rather than the pregnant woman.
How Maternal Antibodies Protect the Baby
The reason recurrent infections are so much safer than new ones ultimately comes down to maternal antibodies crossing the placenta. Research has confirmed that HSV-specific neutralizing antibodies are present in newborns whose mothers are immune, meaning the baby enters the world with a borrowed defense system.22PubMed Central. Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity Animal studies have taken this further, showing that maternal antibodies do not just circulate in the blood but actually accumulate in neural tissue, the very place where HSV does its worst damage. In mouse models, this antibody presence in the nervous system completely prevented neurological disease and death following HSV exposure.23PubMed Central. Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease
This work has practical implications beyond current pregnancy management. Researchers are actively developing maternal vaccines that could boost HSV-specific antibody levels before delivery, potentially protecting babies even when viral exposure occurs. A replication-defective vaccine candidate has already shown promise in animal models, preventing both death and neurological damage in offspring. If such a vaccine reaches clinical use, it could dramatically change the calculus for women who acquire HSV during pregnancy, giving their babies a protective antibody buffer that a natural primary infection does not provide in time.
When HIV Is Also in the Picture
Women living with both HIV and HSV-2 face a compounded problem. HIV weakens the immune system’s ability to keep HSV in check, which translates to more frequent viral shedding. In one study, genital HSV was detected in about 31% of HIV-positive, HSV-2-infected women at the time of delivery, compared with roughly 10% of HIV-negative women. That is a roughly threefold increase in the likelihood of shedding virus during labor.24PubMed Central. Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor More shedding means more opportunity for the baby to be exposed, making suppressive antiviral therapy and cesarean delivery planning even more critical in this population. Managing both infections simultaneously requires close coordination between obstetric and infectious disease teams.
The Emotional Weight of a Diagnosis During Pregnancy
Getting diagnosed with genital herpes at any time carries a heavy psychosocial burden, but learning about it during pregnancy adds a specific and visceral fear: the possibility of harming the baby. Qualitative research on people receiving a new HSV-2 diagnosis has documented a wide range of emotional responses, from distress and sadness to feeling like “damaged goods” and fearing social stigma. Among the ongoing concerns, fear of transmitting the virus to a newborn stood out as a persistent source of anxiety.25Sexually Transmitted Infections. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment
For pregnant women, this anxiety is amplified by the stakes. Even when the medical reality is reassuring, as it is for most women with recurrent herpes, the emotional experience of managing an HSV diagnosis during pregnancy can be isolating. Good counseling should include not just the medical facts about low transmission risk with suppressive therapy and appropriate delivery planning, but also acknowledgment of the stigma and fear that come with the diagnosis. The evidence strongly suggests that most women with known genital herpes who follow recommended management will deliver healthy babies, and hearing that clearly and repeatedly from a trusted provider can make a meaningful difference in how a woman experiences her pregnancy.
How Neonatal Herpes Treatment Has Evolved
The treatment of neonatal HSV has changed substantially over the past few decades. The first antiviral used for this purpose, vidarabine, was introduced in the late 1970s after earlier drugs proved too toxic. In the 1980s, acyclovir replaced vidarabine because it was easier to administer and had a better safety profile.26PubMed Central. Prevention and Treatment of Neonatal Herpes Simplex Virus Infection The more recent shift to high-dose acyclovir was driven by trial data showing that higher doses substantially improved survival in disseminated disease. Babies treated with the higher dose were also more likely to be developmentally normal at one year of age, though the confidence interval on that particular finding was wide. After completing the initial course of intravenous treatment, many infants now receive oral acyclovir suppression for six months to reduce the risk of recurrent skin outbreaks and further neurological damage. Each of these incremental advances has chipped away at what was once a devastating prognosis, though the disease remains serious enough that prevention through maternal management is always preferable to treatment after the fact.